Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 8, 2013, Pages 1938-1939

  Calcagno, A ^a   Trentini, L ^a   Marinaro, L ^a   Montrucchio, C ^a   D'Avolio A , ^a   Ghisetti, V ^b   Di Perri, G ^a   Bonora, S ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

Antiretrovirals; Cord blood concentrations; Pharmacokinetics; Virological failure; Ws gIQ

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; INDINAVIR; MARAVIROC; RALTEGRAVIR; SAQUINAVIR; TENOFOVIR;

CASE REPORT; DRUG TREATMENT FAILURE; FEMALE; FETOMATERNAL TRANSFUSION; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PATIENT COMPLIANCE; PREGNANCY TEST; PREGNANT WOMAN; VIRUS LOAD;

ANTIRETROVIRALS; CORD BLOOD CONCENTRATIONS; PHARMACOKINETICS; VIROLOGICAL FAILURE; WS GIQ;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIDAZINES; RNA, VIRAL; SULFONAMIDES; TREATMENT FAILURE; TRIAZOLES; VIRAL LOAD;

EID: 84880751714     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt095     Document Type: Letter

References (10)

1. van der Lugt J, Colbers A, Burger D. Clinical pharmacology of HIV protease inhibitors in pregnancy. Curr Opin HIV AIDS 2008; 3: 620-6.
2. Ripamonti D, Cattaneo D, Cortinovis M et al. Transplacental passage of ritonavir-boosted darunavir in two pregnant women. Int J STD AIDS 2009; 20: 215-6.
3. Pacanowski J, Bollens D, Poirier JM.et al. Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient. AIDS 2009; 23: 1923-4.
4. Pinnetti C, Tamburrini E, Ragazzoni E.et al. Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1. Antivir Ther 2010; 15: 127-9.
5. Ivanovic J, Bellagamba R, Nicastri E.et al. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS 2010; 24: 1083-4.
6. Prezista package insert. http://www.accessdata.fda.gov/drugsatfda docs/label/2013/021976s029,202895s006lb.pdf (8 February 2013, date last accessed).
7. Gonzalez de Requena D, Bonora S, Viganò O.et al. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. J Antimicrob Chemother 2011; 66: 192-200.
8. D'Avolio A, Siccardi M, Sciandra M.et al. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 859: 234-40.
9. D'Avolio A, Simiele M, Baietto L.et al. A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. Ther Drug Monit 2010; 32: 86-92.
10. Zorrilla C, Wright R, Osiyemi O.et al. Total and unbound darunavir (DRV) pharmacokinetics (PK) in HIV-1-infected pregnant women. J Int AIDS Soc 2012; 15: 18340.